Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,595 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study.
Belge G, Dumlupinar C, Nestler T, Klemke M, Törzsök P, Trenti E, Pichler R, Loidl W, Che Y, Hiester A, Matthies C, Pichler M, Paffenholz P, Kluth L, Wenzel M, Sommer J, Heinzelbecker J, Schriefer P, Winter A, Zengerling F, Kramer MW, Lengert M, Frey J, Heidenreich A, Wülfing C, Radtke A, Dieckmann KP. Belge G, et al. Among authors: che y. Clin Cancer Res. 2024 Jan 17;30(2):404-412. doi: 10.1158/1078-0432.CCR-23-0730. Clin Cancer Res. 2024. PMID: 37967143 Free PMC article.
Late relapsing germ cell tumors with elevated tumor markers.
Che Y, Lusch A, Winter C, Große Siemer R, Buddensieck C, Albers P, Hiester A. Che Y, et al. World J Urol. 2022 Feb;40(2):363-371. doi: 10.1007/s00345-021-03833-z. Epub 2021 Sep 13. World J Urol. 2022. PMID: 34518930 Free PMC article.
Misuse of tumor marker levels leads to an insufficient International Germ Cell Consensus Classification (IGCCCG) risk group assignment and impaired treatment.
Majewski M, Paffenholz P, Ruf C, Che Y, Seidel C, Heinzelbecker J, Schmelz HU, Matthies C, Albers P, Bokemeyer C, Heidenreich A, Pichler M, Nestler T; GTCSG (German Testicular Cancer Study Group). Majewski M, et al. Among authors: che y. Cancer Med. 2023 Aug;12(16):16829-16836. doi: 10.1002/cam4.6304. Epub 2023 Jul 1. Cancer Med. 2023. PMID: 37392170 Free PMC article.
Assessing the risk to develop a growing teratoma syndrome based on molecular and epigenetic subtyping as well as novel secreted biomarkers.
Pongratanakul P, Bremmer F, Pauls S, Poschmann G, Kresbach C, Parmaksiz F, Skowron MA, Fuß J, Stephan A, Paffenholz P, Stühler K, Schüller U, Ströbel P, Heidenreich A, Che Y, Albers P, Nettersheim D. Pongratanakul P, et al. Among authors: che y. Cancer Lett. 2024 Mar 31;585:216673. doi: 10.1016/j.canlet.2024.216673. Epub 2024 Jan 29. Cancer Lett. 2024. PMID: 38296184 Free article.
Serum Levels of MicroRNA-371a-3p for Predicting the Histology of Postchemotherapy Residual Masses of Germ Cell Tumours.
Dieckmann KP, Grobelny F, Soave A, Che Y, Nestler T, Matthies C, Heinzelbecker J, Winter A, Heidenreich A, Niemzok T, Dumlupinar C, Angerer M, Wülfing C, Paffenholz P, Belge G. Dieckmann KP, et al. Among authors: che y. Eur Urol Focus. 2024 May 9:S2405-4569(24)00064-6. doi: 10.1016/j.euf.2024.05.002. Online ahead of print. Eur Urol Focus. 2024. PMID: 38729824 Free article.
Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets.
Bremmer F, Pongratanakul P, Skowron M, Che Y, Richter A, Küffer S, Reuter-Jessen K, Bohnenberger H, Pauls S, Kresbach C, Schüller U, Stühler K, Ströbel P, Albers P, Nettersheim D. Bremmer F, et al. Among authors: che y. Br J Cancer. 2023 Nov;129(10):1580-1589. doi: 10.1038/s41416-023-02425-5. Epub 2023 Sep 19. Br J Cancer. 2023. PMID: 37726478 Free PMC article.
1,595 results